Clinical response, survival, and relapse. (A) Study design. (B) Skin, gastrointestinal (GI), joint/fascia (JF), lung, and liver cGVHD scores at baseline, week 8, and week 16. cGVHD severity at baseline (week 0) and overall responses at week 8 and week 16. (C) OS, PFS, and cGVHD PFS (CPFS) for all patients. (D) OS for responders (R) and nonresponders (NR).